A Healthcare Technology Company

Shaping the future of non-invasive diagnosis with artificial intelligence.

Uniquely Positioned among Non-invasive technologies

Just needs a single blood draw Diagnostics powered by Artificial intelligence
using broadly available biomarkers that provides diagnostic accuracy equivalent to a biopsy.

Fibronostics patent technology

Patent Technology

CPT Code: 0166U

Fibronostics patent technology

De Novo 510K

(in Progress)

Fibronostics CE mark

CE mark

(Conformité Européenne)

Fibronostics patent technology

CLIA Certified

Fibronostics patent technology

Artificial Technology based Platform

LIVERFASt™ has now been granted CPT Code.

The American Medical Association (AMA) and The Centers for Medicare & Medicaid Services (CMS) awarded LIVERFASt™ a CPT Code with the highest reimbursement fee in its category!

Learn More

70,000+

Patients Screened

50+

Network Health System

30+

Laboratories

900+

Medical centre & Pharmacies

Complete Liver Diagnosis

LIVERFASt™ – from Early Stage to Late Stage
for NAFLD , NASH Cirrhosis & Hepatocellular Carcinoma.

Fibronostics Diagnosis

Diagnosis

Non-invasive disease detection means earlier diagnosis and earlier intervention for better patient outcomes.

Fibronostics Screening

Screening

Risk stratification among large patient populations allows for better management leading to cost reductions.

Fibronostics Monitoring

Monitoring

Regular surveillance with easily repeatable non-invasive diagnostics enables optimized disease management.

Non-invasive solutions for diagnosis, screening and monitoring.

X

Fibronostics Appoints Dr. Stephen A. Harrison to its Board of Advisors

Learn more